TURKOVAC
Sign in to saveAlso known as ERUCOV-VAC
Turkovac (pronunciation: Help:IPA/Turkish|) is a COVID-19 vaccine developed by Turkish Ministry of Health and Erciyes University. __TOC__ == Clinical trials == In November 2020, Turkovac started on phase I trials with 44 participants in Turkey.
In the Vinony graph
Within Vinony's link graph, TURKOVAC is referenced by 1,280 other articles, and connects out to SARS-CoV-2, Gam-COVID-Vac and COVID-19 pandemic in Italy.
It is catalogued under topics including Chemical pages without ChemSpiderID, Chemical pages without DrugBank identifier and Drugs missing an ATC code.
Its subject is documented across 10 Wikipedia language editions.
Key facts
- Drug.drug_name
- Turkovac
- Drug.type
- vaccine
- Drug.target
- SARS-CoV-2
- Drug.vaccine_type
- inactivated
- Drug.legal_status
- Full list of Turkovac authorizations
- Drug.routes_of_administration
- Intramuscular
- Drug.CAS_number
- 2695585-27-2
- Drug.synonyms
- Erucov-Vac
via Wikipedia infobox
~1 min read
Encyclopedic overview
3 sectionsContents
- Clinical trials
- Authorization
- References
Turkovac (pronunciation: Help:IPA/Turkish|) is a COVID-19 vaccine developed by Turkish Ministry of Health and Erciyes University. __TOC__ == Clinical trials == In November 2020, Turkovac started on phase I trials with 44 participants in Turkey.
In February 2021, Turkovac started on phase II trials with 250 participants in Turkey.
Excerpted from Wikipedia’s “TURKOVAC” article, available under the CC BY-SA 4.0 licence.